Selective regulation of osteoblastic OPG and RANKL by dehydroepiandrosterone through activation of the estrogen receptor β-mediated MAPK signaling pathway

Hormone and Metabolic Research

Volumn 44, Issue 7, 2012, Pages 494-500

  Wang, Y D ^a   Tao, M F ^a   Wang, L ^b   Cheng, W W ^a   Wan, X P ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

dehydroepiandrosterone; estrogen receptor ; OPG; RANKL

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUTAMIDE; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PRASTERONE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OSTEOBLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MAP KINASE SIGNALING SYSTEM; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND; RNA, MESSENGER;

EID: 84862213629     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1311567     Document Type: Article

References (37)

1. Boyle W J, Simonet W S, Lacey D L. Osteoclast differentiation and activation. Nature: 2003; 423 6937 337 342 (Pubitemid 40852708)
2. Enserink M. Women's health. The vanishing promises of hormone replacement. Science: 2002; 297 5580 325 326 (Pubitemid 34790736)
3. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik J A, Lee H J, Hanada R, Joshi P A, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy C J, Widschwendter M, Schett G, Penninger J M. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature: 2010; 468 7320 98 102
4. Balasch J. Sex steroids and bone: current perspectives. Hum Reprod Update: 2003; 9 207 222 (Pubitemid 36827059)
5. Fedele S, Porter S R, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino P G, Broccoletti R, Musciotto A, Di Fede O, Lazarovici T S, Campisi G, Yarom N. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med: 2010; 123 1060 1064
6. Frank G R. Growth and estrogen. Growth Genet Horm: 2000; 16 1 5
7. Chen J R, Kousteni S, Bellido T, Han L, DiGregorio G B, Jilka R L, Manolagas S C. Gender-independent induction of murine osteoclast apoptosis in vitro by either estrogens or non-aromatizable androgens. J Bone Miner Res: 2001; 16 01 S159
8. Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, Fujimoto Y, Miyazaki H, Salen G. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids: 2003; 68 73 83 (Pubitemid 35418305)
9. Schwartz A G, Pashko L, Whitcomb J M. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol: 1986; 14 357 362 (Pubitemid 16000926)
10. Araghi-Niknam M, Ardestani S K, Molitor M, Inserra P, Eskelson C D, Watson R R. Dehydroepiandrosterone (DHEA) sulfate prevents reduction in tissue vitamin E and increased lipid peroxidation due to murine retrovirus infection of aged mice. Proc Soc Exp Biol Med: 1998; 218 210 217
11. Matsuzaki Y, Honda A. Dehydroepiandrosterone and its derivatives: potentially novel anti-proliferative and chemopreventive agents. Curr Pharm Des: 2006; 12 3411 3421 (Pubitemid 44375466)
12. Cormier C, Souberbielle J C, Kahan A. DHEA in bone and joint diseases. Joint Bone Spine: 2001; 68 588 594 (Pubitemid 34037296)
13. Wang L, Wang Y D, Wang W J, Li D J. Differential regulation of dehydroepiandrosterone and estrogen on bone and uterus in ovariectomized mice. Osteoporos Int: 2009; 20 79 92
14. Wang Y D, Wang L, Li D J, Wang W J. Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL. Cell Mol Immunol: 2006; 3 41 45
15. de Cremoux P, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon M F, De Rycke Y, Asselain B, Magdelénat H. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol: 2002; 64 507 515 (Pubitemid 34874854)
16. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology: 2001; 142 4120 4130 (Pubitemid 32802685)
17. Collado M, Medema R H, Garcia-Cao I, Dubuisson M L, Barradas M, Glassford J, Rivas C, Burgering B M, Serrano M, Lam E W. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem: 2000; 275 21960 21968 (Pubitemid 30621769)
18. Harada S, Rodan G A. Control of osteoblast function and regulation of bone mass. Nature: 2003; 423 6937 349 355 (Pubitemid 40852710)
19. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun: 1998; 250 229 234 (Pubitemid 28463860)
20. Kong Y Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch E R, Van G, Nguyen L T, Ohashi P S, Lacey D L, Fish E, Boyle W J, Penninger J M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature: 1999; 402 6759 304 309 (Pubitemid 129516268)
21. Canon J R, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik P J, Dougall W C. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis: 2008; 25 119
22. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res: 2003; 63 2096
23. Feeley B T, Liu N Q, Conduah A H, Krenek L, Roth K, Dougall W C, Huard J, Dubinett S, Lieberman J R. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res: 2006; 21 1571 1580 (Pubitemid 44484602)
24. Karsenty G, Wagner E F. Reaching a genetic and molecular understanding of skeletal development. Dev Cell: 2002; 2 389 406 (Pubitemid 34436569)
25. Rodan G A, Martin T J. Therapeutic approaches to bone diseases. Science: 2000; 289 1508 1514
26. Teitelbaum S L, Ross F P. Genetic regulation of osteoclast development and function. Nat Rev Genet: 2003; 4 638 649 (Pubitemid 36917505)
27. Pike M C, Peters R K, Cozen W, Probst-Hensch N M, Felix J C, Wan P C, Mack T M. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst: 1997; 89 1110 1116 (Pubitemid 27337924)
28. Gonzalez-Suarez E, Jacob A P, Jones J, Miller R, Roudier-Meyer M P, Erwert R, Pinkas J, Branstetter D, Dougall W C. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature: 2010; 468 7320 103 107
29. Chambliss K L, Yuhanna I S, Anderson R G, Mendelsohn M E, Shaul P W. ERbeta has nongenomic action in caveolae. Mol Endocrinol: 2002; 16 938 946 (Pubitemid 34478532)
30. Manolagas S C, Kousteni S, Jilka R L. Sex steroids and bone. Recent Prog Horm Res: 2002; 57 385 409
31. Kousteni S, Bellido T, Plotkin L I, O'Brien C A, Bodenner D L, Han L, Han K, DiGregorio G B, Katzenellenbogen J A, Katzenellenbogen B S, Roberson P K, Weinstein R S, Jilka R L, Manolagas S C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell: 2001; 104 719 730 (Pubitemid 32241022)
32. Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev: 2002; 123 1101 1106 (Pubitemid 34603093)
33. Viereck V, Gründker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch K H, Raddatz D, Emons G, Hofbauer L C. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab: 2003; 88 4206 4213 (Pubitemid 37153721)
34. Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Spelsberg T C, Riggs B L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology: 1999; 140 4367 4370 (Pubitemid 30647136)
35. Wang Y, Li L Z, Zhang Y L, Zhu Y Q, Wu J, Sun W J. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. Mol Cell Endocrinol: 2011; 337 43 51
36. Sorensen M G, Henriksen K, Dziegiel M H, Tankó L B, Karsdal M A. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature steoclasts. DNA Cell Biol: 2006; 25 475 483 (Pubitemid 44267068)
37. Wattanaroonwong N, Schoenmaker T, de Vries T J, Everts V. Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. Arch Oral Biol: 2011; 56 212 219